" class="no-js "lang="en-US"> TrueBinding - Medtech Alert
Saturday, June 21, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
TrueBinding | MTA

TrueBinding

About TrueBinding

TrueBinding
TrueBinding Inc. is a clinical-stage biotherapeutics company focused on pioneering the development of innovative monoclonal antibodies for the treatment of some of the most challenging neurodegenerative diseases, including Alzheimer's disease (AD), as well as stroke, oncology and other serious diseases.

Related Story

Diseases

 TrueBinding Granted Type B End-of-Phase 2 Meeting with FDA for Discussion of Accelerated Development Pathway for TB006 Alzheimer's Disease Treatment | MTA

TrueBinding Granted Type B End-of-Phase 2 Meeting with FDA for Discussion of Accelerated Development Pathway for TB006 Alzheimer's Disease Treatment

March 16 2023

TrueBinding, a clinical-stage biotherapeutic company creating new and exciting molecules for applications in neurodegenerative and […]